[
  {
    "ts": null,
    "headline": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?",
    "summary": "We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […]",
    "url": "https://finnhub.io/api/news?id=5cf4ff087101d537a7e41182bdb48e03b64c09cab86a7889737050ee576dc1f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743525776,
      "headline": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?",
      "id": 133655250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […]",
      "url": "https://finnhub.io/api/news?id=5cf4ff087101d537a7e41182bdb48e03b64c09cab86a7889737050ee576dc1f3"
    }
  },
  {
    "ts": null,
    "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
    "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit",
    "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743522637,
      "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
      "id": 133645467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit",
      "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf"
    }
  },
  {
    "ts": null,
    "headline": "VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates",
    "summary": "Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.",
    "url": "https://finnhub.io/api/news?id=567f789ed0c55726d6edac0d9a9db9ba0f45a81a73c27ad28d89b38cd8d7aa2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743519300,
      "headline": "VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates",
      "id": 133655251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.",
      "url": "https://finnhub.io/api/news?id=567f789ed0c55726d6edac0d9a9db9ba0f45a81a73c27ad28d89b38cd8d7aa2e"
    }
  },
  {
    "ts": null,
    "headline": "These biotech names aren't facing 'huge concern' from tariffs",
    "summary": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=3c95152d520015603efbbfe60d018817dd7753417c24b8ffe43796a8e6ed66ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743507025,
      "headline": "These biotech names aren't facing 'huge concern' from tariffs",
      "id": 133645380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=3c95152d520015603efbbfe60d018817dd7753417c24b8ffe43796a8e6ed66ce"
    }
  }
]